Skip to main content

New story in Health from Time: FDA Issues Warning About Hydroxychloroquine for COVID-19



On April 24, the U.S. Food and Drug Administration (FDA) issued a MedWatch Safety Alert about the use of hydroxychloroquine or chloroquine for treating COVID-19.

After preliminary studies hinted that hydroxychloroquine may help some patients with severe COVID-19 symptoms to improve, the FDA issued an emergency use authorization (EUA) to allow doctors to use the drug on hospitalized patients whose symptoms are not improving. Several studies were also launched to study its effects as a COVID-19 treatment.

However, hydroxychloroquine can have negative effects on the heart, contributing to abnormal heart rhythms that can be life-threatening. For those with existing heart problems, the dangers could be even greater, especially if the drug is combined with the antibiotic azithromycin, as some researchers treating COVID-19 patients have done. The American Heart Association, the American College of Cardiology and the Heart Rhythm Society jointly published cautionary guidelines recommending that doctors stop using hydroxychloroquine on patients at any sign of heart trouble.

The drugs are approved for treating malaria, and in the case of hydroxychloroquine, also for treating autoimmune disorders like rheumatoid arthritis and lupus. (In the U.S., hydroxychloroquine is more common since the malaria parasite is largely resistant to chloroquine.) For people taking the drug for an autoimmune disorder, their doctors monitor for signs of adverse heart events and can adjust dosage as needed.

The FDA’s safety alert doesn’t say those patients should stop taking the drugs they need, but instead warns general consumers to “not buy these medicines from online pharmacies without a prescription from your health care professional.” The alert stresses that hydroxychloroquine and chloroquine “should be used for COVID-19 only where patients can be appropriately monitored in the hospital as required by the EUA or are enrolled in a clinical trial with appropriate screening and monitoring.”

The FDA says that neither drug has been proven safe and effective in treating COVID-19. In fact, a study published on April 23 involving 368 COVID-19 patients at U.S. Veterans Health Administration hospitals found that taking hydroxychloroquine alone, or in combination with azithromycin, did not reduce the need for a ventilator compared to those not taking the drugs. Further, people taking hydroxychloroquine alone had a higher risk of dying during the study than those not taking the drug. Researchers in China came to a similar conclusion in a study of 150 COVID-19 patients randomly assigned to receive hydroxychloroquine or the current standard of care: after a month, both groups had similar symptom profiles, and showed similar levels of the virus, suggesting that the drug wasn’t clearing the COVID-19 virus in a significant way.

The National Institutes of Health is conducting an ongoing study of hydroxychloroquine among hospitalized patients, as is Novartis, whose Sandoz division makes a generic version of the drug.

Labels:

Popular posts from this blog

New story in Health from Time: Here’s How Quickly Coronavirus Is Spreading in Your State

The novel coronavirus pandemic is a global crisis, a national emergency and a local nightmare. But while a great deal of the focus in the U.S. has been on the federal government’s response, widely criticized as slow and halting , the picture on the ground remains very different in different parts of the country. A TIME analysis of the per capita spread of the epidemic in all 50 states and Washington, D.C. found considerable range in the rate of contagion, and, in some parts of the country, a significant disparity compared to the national figure. The U.S., unlike nations such as South Korea and now Italy , has yet to show signs of bringing the runaway spread of the virus under control. However, while no single state is yet showing strong signs of bending the curve , some are faring much worse than others. The following graphic plots the rise in the total confirmed cases of COVID-19 per 100,000 residents in each state, plotted by the day that each state reported its first case.
Read more

New story in Health from Time: We Need to Take Care of the Growing Number of Long-term COVID-19 Patients

On July 7, 2020, the Boston Red Sox pitcher Eduardo Rodriguez tested positive for the new coronavirus. He was scheduled to start Opening Day for the Sox, but the virus had other plans— damaging Rodriguez’s heart and causing a condition called myocarditis (inflammation of the heart muscle). Now the previously fit 27-year old ace left-hander must sit out the 2020 season to recover. Rodriguez is not alone in having heart damage from SARS-CoV-2, the virus that causes COVID-19. In a new study done in Germany, researchers studied the hearts of 100 patients who had recently recovered from COVID-19. The findings were alarming: 78 patients had heart abnormalities, as shown by a special kind of imaging test that shows the heart’s structure (a cardiac MRI), and 60 had myocarditis. These patients were mostly young and previously healthy . Several had just returned from ski trips. While other studies have shown a lower rate of heart problems—for example, a study of 416 patients hosp
Read more

New story in Health from Time: U.S. Inmates ‘Mistakenly’ Received COVID-19 Stimulus Checks. Now, the IRS Wants That Money Back

(BOISE, Idaho) — Hundreds of thousands of dollars in coronavirus relief payments have been sent to people incarcerated across the United States, and now the IRS is asking state officials to help claw back the cash that the federal tax agency says was mistakenly sent. The legislation authorizing the payments during the pandemic doesn’t specifically exclude jail or prison inmates, and the IRS has refused to say exactly what legal authority it has to retrieve the money. On its website, it points to the unrelated Social Security Act, which bars incarcerated people from receiving some types of old-age and survivor insurance benefit payments. “I can’t give you the legal basis. All I can tell you is this is the language the Treasury and ourselves have been using,” IRS spokesman Eric Smith said. “It’s just the same list as in the Social Security Act.” Read more: ‘A Double Whammy.’ Those Who Most Need The $1,200 Stimulus Checks May Wait the Longest To Get Them Tax attorney Kell
Read more